Patients with aortic stenosis were excluded from earlier trials of the SGLT2 inhibitor, but new data confirm they too can ...
The follow-up brought little surprise, with investigators pleased the risk of death/disabling stroke remained on par with ...
Findings from the first 500 patients treated with the Trilogy system met noninferiority for both safety and efficacy.
Experts are dismayed, disappointed, and confused, but many say this isn’t the end of cerebral embolic protection for TAVI.
There are worries about delayed complications, but many places won’t get paid if AF patients don’t spend the night in ...
Injectable semaglutide has better bioavailability, researchers say, but the many patients who want an oral drug are an unmet ...
On top of noninferior efficacy, the trial showed patients had less bleeding with 2.5 mg vs 5.0 mg twice daily over 12 months.
The “neutral” trial, troubled by the COVID-19 pandemic, found that intensive medical therapy didn’t lower events in INOCA.
While the exact mechanism is unknown, the data suggest a multitude of benefits independent of large weight loss.
Bouffant caps, beard covers, and more—the idea is to prevent infection. Some say the requirements are overkill.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results